Tamar Ziehm

445 total citations
18 papers, 354 citations indexed

About

Tamar Ziehm is a scholar working on Physiology, Molecular Biology and Oncology. According to data from OpenAlex, Tamar Ziehm has authored 18 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Physiology, 7 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Tamar Ziehm's work include Alzheimer's disease research and treatments (14 papers), Amino Acid Enzymes and Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Tamar Ziehm is often cited by papers focused on Alzheimer's disease research and treatments (14 papers), Amino Acid Enzymes and Metabolism (6 papers) and Drug Transport and Resistance Mechanisms (5 papers). Tamar Ziehm collaborates with scholars based in Germany, United States and Australia. Tamar Ziehm's co-authors include Dieter Willbold, Janine Kutzsche, Lothar Gremer, Antje Willuweit, Karl‐Josef Langen, N. Jon Shah, Markus Tusche, Oleksandr Brener, Nan Jiang and Inga Kadish and has published in prestigious journals such as PLoS ONE, Chemical Communications and Scientific Reports.

In The Last Decade

Tamar Ziehm

18 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tamar Ziehm Germany 13 234 174 81 61 53 18 354
Gregor Larbig Germany 9 146 0.6× 197 1.1× 89 1.1× 114 1.9× 26 0.5× 12 405
Anke Schmauder Germany 8 263 1.1× 239 1.4× 41 0.5× 51 0.8× 41 0.8× 8 438
Nicolò Tonali France 12 141 0.6× 238 1.4× 41 0.5× 49 0.8× 47 0.9× 31 375
Gerald Gellermann Germany 7 404 1.7× 475 2.7× 78 1.0× 41 0.7× 33 0.6× 9 638
Yorimasa Suwa Japan 4 189 0.8× 151 0.9× 54 0.7× 90 1.5× 15 0.3× 5 346
Charlotte Revill United Kingdom 9 259 1.1× 319 1.8× 46 0.6× 34 0.6× 75 1.4× 12 555
Filippa Lo Cascio United States 9 178 0.8× 186 1.1× 33 0.4× 48 0.8× 18 0.3× 11 373
Kelvin Stott United Kingdom 7 228 1.0× 371 2.1× 89 1.1× 77 1.3× 22 0.4× 9 552
Janet C. Saunders United Kingdom 5 239 1.0× 280 1.6× 44 0.5× 36 0.6× 23 0.4× 7 441
Kwangwook Ahn United States 8 237 1.0× 249 1.4× 81 1.0× 86 1.4× 45 0.8× 10 411

Countries citing papers authored by Tamar Ziehm

Since Specialization
Citations

This map shows the geographic impact of Tamar Ziehm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tamar Ziehm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tamar Ziehm more than expected).

Fields of papers citing papers by Tamar Ziehm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tamar Ziehm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tamar Ziehm. The network helps show where Tamar Ziehm may publish in the future.

Co-authorship network of co-authors of Tamar Ziehm

This figure shows the co-authorship network connecting the top 25 collaborators of Tamar Ziehm. A scholar is included among the top collaborators of Tamar Ziehm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tamar Ziehm. Tamar Ziehm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Vidovic, Natascha, André Frenzel, Philipp Kühn, et al.. (2021). Effects of a Multimerized Recombinant Autoantibody Against Amyloid-β. Neuroscience. 463. 355–369. 3 indexed citations
2.
Zafiu, Christian, Tamar Ziehm, Karl‐Josef Langen, et al.. (2018). Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2. Neurobiology of Disease. 124. 36–45. 12 indexed citations
3.
Ziehm, Tamar, Markus Tusche, Oleksandr Brener, et al.. (2018). In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease. Journal of Alzheimer s Disease. 64(3). 859–873. 10 indexed citations
4.
Müller‐Schiffmann, Andreas, Tamar Ziehm, Andreas Stadler, et al.. (2018). Biophysical insights from a single chain camelid antibody directed against the Disrupted-in-Schizophrenia 1 protein. PLoS ONE. 13(1). e0191162–e0191162. 5 indexed citations
5.
Donner, L, Lothar Gremer, Tamar Ziehm, et al.. (2018). Relevance of N-terminal residues for amyloid-β binding to platelet integrin α IIb β 3 , integrin outside-in signaling and amyloid-β fibril formation. Cellular Signalling. 50. 121–130. 17 indexed citations
6.
Ziehm, Tamar, Michael Huber, Yaw Asare, et al.. (2018). LPS-mediated cell surface expression of CD74 promotes the proliferation of B cells in response to MIF. Cellular Signalling. 46. 32–42. 29 indexed citations
7.
Munte, Cláudia Elisabeth, Thomas van Groen, Inga Kadish, et al.. (2018). Inhibition of amyloid Aβ aggregation by high pressures or specificd-enantiomeric peptides. Chemical Communications. 54(26). 3294–3297. 12 indexed citations
8.
Ziehm, Tamar, Alexander K. Buell, & Dieter Willbold. (2018). Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d-Peptides in the Interaction with Amyloid-Beta Monomers. ACS Chemical Neuroscience. 9(11). 2679–2688. 12 indexed citations
9.
Ziehm, Tamar, Nan Jiang, Markus Tusche, et al.. (2017). Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. European Journal of Pharmaceutical Sciences. 114. 93–102. 11 indexed citations
10.
Groen, Thomas van, Oleksandr Brener, Lothar Gremer, et al.. (2017). The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Scientific Reports. 7(1). 16275–16275. 47 indexed citations
11.
Reiß, Kerstin, Lothar Gremer, Justin Lecher, et al.. (2017). Pyroglutamate-Modified Amyloid-β(3–42) Shows α-Helical Intermediates before Amyloid Formation. Biophysical Journal. 112(8). 1621–1633. 21 indexed citations
12.
Ziehm, Tamar, Markus Tusche, Dagmar Jürgens, et al.. (2017). Aβ oligomer eliminating compounds interfere successfully with pEAβ(3–42) induced motor neurodegenerative phenotype in transgenic mice. Neuropeptides. 67. 27–35. 8 indexed citations
13.
Klein, Antonia, Tamar Ziehm, Thomas van Groen, et al.. (2017). Optimization of d-Peptides for Aβ Monomer Binding Specificity Enhances Their Potential to Eliminate Toxic Aβ Oligomers. ACS Chemical Neuroscience. 8(9). 1889–1900. 23 indexed citations
14.
Jiang, Nan, Tamar Ziehm, Janine Kutzsche, et al.. (2016). Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease. European Journal of Pharmaceutical Sciences. 89. 31–38. 23 indexed citations
15.
Klein, Antonia, Tamar Ziehm, Markus Tusche, et al.. (2016). Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. PLoS ONE. 11(4). e0153035–e0153035. 19 indexed citations
16.
Ziehm, Tamar, Oleksandr Brener, Thomas van Groen, et al.. (2016). Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. ACS Chemical Neuroscience. 7(8). 1088–1096. 26 indexed citations
17.
Jiang, Nan, Tamar Ziehm, Jörg Mauler, et al.. (2015). Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease. PLoS ONE. 10(6). e0128553–e0128553. 39 indexed citations
18.
Jiang, Nan, Tamar Ziehm, Janine Kutzsche, et al.. (2015). Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers. Pharmaceutical Research. 33(2). 328–336. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregor Larbig Breakdown of academic impact, for papers by Anke Schmauder Breakdown of academic impact, for papers by Nicolò Tonali Breakdown of academic impact, for papers by Gerald Gellermann Breakdown of academic impact, for papers by Yorimasa Suwa Breakdown of academic impact, for papers by Charlotte Revill Breakdown of academic impact, for papers by Filippa Lo Cascio Breakdown of academic impact, for papers by Kelvin Stott Breakdown of academic impact, for papers by Janet C. Saunders Breakdown of academic impact, for papers by Kwangwook Ahn
Rankless by CCL
2026